Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the Management of Patent Ductus Arteriosus (PDA) in Preterm Infants and Variations in Attitude in Clinical Practice: A Flight Around the World

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)

Volume 22, 38 Issues, 2015

Download PDF Flyer

Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 6th of 59 in Chemistry & Medicinal
  • 47th of 254 in Pharmacology & Pharmacy
  • 81st of 289 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.853
5 - Year: 4.115

Select Language (选择语言):

Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the Management of Patent Ductus Arteriosus (PDA) in Preterm Infants and Variations in Attitude in Clinical Practice: A Flight Around the World

Current Medicinal Chemistry, 21(27): 3132-3152.

Author(s): R. Irmesi, M.A. Marcialis, J.V.D. Anker and V. Fanos

Affiliation: Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, Azienda Ospedaliero Universitaria and University of Cagliari, Cagliari, Italy.


The primary objective of this review is to verify if there are differences in the diagnostic and therapeutic strategies in cases of PDA employed in different NICUs that might help explain the different percentages of duct closure, surgical ligation and outcome in these vulnerable patients. The secondary objective is to document if the selection of a specific NSAID and/or the way of administration are based on factors such as costs and local availability of drugs, as well as influenced by clinical and haemodynamic parameters, potential risks, local experience and the existing literature. Data Sources were MEDLINE, EMBASE, Cochrane Library and analysis of the most important papers were performed. We examined a total of 89 trials including 15,657 neonates (with gestational ages between 22 and 35 weeks and study weights between 380 and 2500 g), due to the lack of homogeneity of case studies it was not possible to standardize for gestational age and weight. To simplify, the studies we considered were subdivided into 5 groups corresponding to 5 tables: 1- INDO-prophylaxis (15 trials); 2- IBU-prophylaxis (11 trials); 3- INDO-therapy (18 trials); 4- IBU-therapy (16 trials); 5- IBU vs INDO therapy (29 trials). Each table reports the journal, the reference, the type of study, the number of neonates enrolled, the drugs used, management after failure of the first cycle, percentage of duct closure and adverse effects. Treatment with indomethacin is prescribed prevalently in the United States and Canada. According to the data collected, prolonged treatment and administration of high doses would appear to be more effective. The early administration of indometacin has been associated with gastrointestinal bleeding, renal insufficiency, altered cerebral self-regulation and, especially when administered together with postnatal steroids, it has been correlated with isolated intestinal perforation. Ibuprofen treatment is preferred in Europe but it may be associated with nephrotoxicity and an increase in BDP and ROP, although less frequently compared to indometacin. Indometacin is associated with major nephrotoxicity, as well as with a higher incidence of NEC, intestinal perforations and a reduced cerebral blood flow. Despite this, the administration of ibuprofen does not appear to be without short- and long-term renal adverse effects.


Efficacy, Europe, newborn, NSAIDs, safety, USA.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 21
Issue Number: 27
First Page: 3132
Last Page: 3152
Page Count: 21
DOI: 10.2174/0929867321666140304095434

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science